158 related articles for article (PubMed ID: 25823425)
1. The urokinase lock-therapy for hemodialysis occluded central venous catheters.
Li Cavoli G; Schillaci O; Zagarrigo C; Servillo F; Li Cavoli TV; Palmeri M; Rotolo U
Blood Purif; 2015; 39(1-3):238. PubMed ID: 25823425
[No Abstract] [Full Text] [Related]
2. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
[TBL] [Abstract][Full Text] [Related]
4. Hemodialysis tunneled-cuffed catheter-related atrial thrombus complicated with asymptomatic pulmonary emboli.
Zhang Z; Zhang D
J Vasc Access; 2018 Mar; 19(2):197-198. PubMed ID: 29147998
[No Abstract] [Full Text] [Related]
5. Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.
Van Hulle F; Bonkain F; De Clerck D; Aerden D; Vanwijn I; Tielemans C; Wissing KM
J Vasc Access; 2019 Jan; 20(1):60-69. PubMed ID: 29893163
[TBL] [Abstract][Full Text] [Related]
6. Interventions for restoring patency of occluded central venous catheter lumens (Review).
van Miert C; Hill R; Jones L
Evid Based Child Health; 2013 Mar; 8(2):695–749. PubMed ID: 24482900
[No Abstract] [Full Text] [Related]
7. Is the removal of a central venous catheter always necessary in the context of catheter-related right atrial thrombosis?
Rossi L; Libutti P; Casucci F; Lisi P; Teutonico A; Basile C; Lomonte C
J Vasc Access; 2019 Jan; 20(1):98-101. PubMed ID: 29749281
[TBL] [Abstract][Full Text] [Related]
8. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
Clase CM; Crowther MA; Ingram AJ; Cinà CS
J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
[TBL] [Abstract][Full Text] [Related]
9. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters.
Castner D
Nephrol Nurs J; 2001 Aug; 28(4):403-4, 407-10. PubMed ID: 12143462
[TBL] [Abstract][Full Text] [Related]
11. Urokinase: new indication. Thrombosed venous and dialysis catheters: when heparin fails. Urokinase clears about 75% of thrombosed venous catheters intended for long-term use with a dose-related increase in the bleeding risk.
Prescrire Int; 2009 Jun; 18(101):118. PubMed ID: 19637430
[No Abstract] [Full Text] [Related]
12. Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters (PASSPORT 1).
Kumwenda MJ; Mitra S; Khawaja A; Inston N; Nightingale P
J Vasc Access; 2019 Nov; 20(6):752-759. PubMed ID: 31466489
[TBL] [Abstract][Full Text] [Related]
13. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
[TBL] [Abstract][Full Text] [Related]
14. Lytic therapy in central venous catheters for hemodialysis.
McFarland HF; Dinwiddie L; Ferrell J; Forloines-Lynn S
Nephrol Nurs J; 2002 Aug; 29(4):355-60; quiz 361-2. PubMed ID: 12224368
[TBL] [Abstract][Full Text] [Related]
15. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
Bonkain F; Stolear JC; Catalano C; Vandervelde D; Treille S; Couttenye MM; Dhondt A; Libertalis M; Allamani M; Madhoun P; Van Craenenbroeck AH; Vanommeslaeghe F; Van Hulle F; Durieux P; Van Limberghen I; Tielemans C; Wissing KM
PLoS One; 2021; 16(5):e0251793. PubMed ID: 34015014
[TBL] [Abstract][Full Text] [Related]
16. Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.
Wójtowicz D; Cholewa D; Faba AM; Domańska B; Kokoszka J; Kopacz K; Ficek R; Irzyniec T; Rotkegel SE; Chudek J
Ren Fail; 2018 Nov; 40(1):384-389. PubMed ID: 30010473
[TBL] [Abstract][Full Text] [Related]
17. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
18. Managing dysfunctional central venous access devices: a practical approach to urokinase thrombolysis.
Kumwenda M; Dougherty L; Spooner H; Jackson V; Mitra S; Inston N
Br J Nurs; 2018 Jan; 27(2):S4-S10. PubMed ID: 29368572
[TBL] [Abstract][Full Text] [Related]
19. [Urokinase in the management of occluded PICC lines].
Muller C; Jacquier A; Varoquaux A; Cohen F; Louis G; Gaubert JY; Moulin G; Bartoli JM; Vidal V
J Radiol; 2010 Mar; 91(3 Pt 1):287-91. PubMed ID: 20508559
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of obstruction and thrombosis due to central venous catheterization].
Leititis JU
Klin Padiatr; 1991; 203(6):420-3. PubMed ID: 1758144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
